The Latest Breaking News from Pfizer

Moderna stock and BioNTech stock led a sell-off Monday among Covid vaccine makers after Pfizer slashed its full-year guidance.

Shares of Pfizer are falling before the opening bell as the company cut its full-year outlook, citing declining sales of its COVID-19-related products

Minnesota knew what audience to tailor to, no pun intended.

“Who knew I’d get into the vax wars with Aaron Rodgers, man?”

Doses aren’t arriving at providers’ offices at uniform, predictable intervals. Shipments are largely dependent on individual providers’ ability to work out the logistics of ordering, stocking, training and paperwork.

Pfizer and Campbell Soup see surge in searches and sales after dating rumors

The pharmaceutical industry is poised for sustained long-term growth due to increased investments in drug development and rapid technological advancements. While leading pharma stocks Pfizer (PFE) and Eli Lilly (LLY) stand to benefit, let us analyze which of these giants is poised for more gains this month. Keep reading.

Vaccine uses different technology than Moderna and Pfizer's mRNA targeting strategy

The sell-off in the U.S. stock market has deepened in October, and the Dow Jones Industrial Average is now negative for the year. Amid a challenging macro environment, Berkshire Hathaway, Pfizer, and Coca-Cola look like three good defensive stocks to buy.